Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Sleep apnea, a sleep disorder typically managed with a medical device that aids in breathing, now has its first FDA-approved drug therapy, an Eli ... management. OSA is caused by blockage of the ...

Overall, I am encouraged by the decisions management is making and am optimistic about Lilly's long-term prospects ... On rare occasions, our expert team of analysts issues a “Double Down ...

Despite the disheartening price action, this medical sector giant is still one of the world’s largest research-based biopharmaceutical companies behind Eli Lilly & Co. (NYSE: LLY). Pfizer is ...

Pharmaceutical giant Eli Lilly ... can be that management feels that the stock is undervalued. To me, Montarce's quote implies that management sees a lot of upside for Lilly, given the company's ...

I continue to see Novo Nordisk as a formidable competitor, but the latest updates give Eli Lilly the upper hand in the near and medium term. However, I also think that the valuation differential ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

which is when a person's upper airway is blocked, causing pauses in breathing during sleep. Research has shown that weight loss can help patients with sleep apnea. In two Eli Lilly trials spanning ...

Eli Lilly and Company Stock Performance Shares of Eli Lilly and Company stock opened at $778.07 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio ...